In May 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) conducted a significant raid at Moulton Grange, a Grade II-listed Georgian country house in Northamptonshire, revealing a large-scale operation involving unlicensed weight-loss injections. Approximately 12,000 doses were seized, marking the largest confiscation of such products to date in the UK.
Historic Venue Linked to Illicit Activity
Moulton Grange, a luxury wedding and event venue set in 28 acres of rural grounds, is known for its elegant Georgian facade and period features. Despite its prestigious reputation, the property was found to be involved in the production and storage of weight-loss injections branded as "Alluvi." The seized products included syringes labelled as tirzepatide and retatrutide. Tirzepatide is a medication sold under the brand name Mounjaro by Eli Lilly, but the MHRA confirmed that the seized items were not genuine products from the company. Retatrutide is an experimental obesity drug currently in clinical trials in the United States and is not licensed for use in the UK.
Risks of Unlicensed Medicines
The MHRA emphasised that obtaining prescription-only medicines from unregulated sources poses significant safety risks. Products outside legitimate supply chains lack guarantees regarding their quality, safety, and authenticity. The packaging of the seized injections was described as "sophisticated" and "authentic looking," which could mislead consumers and increase potential harm.
Consumers are advised to only acquire medicines through registered pharmacies with a valid prescription to ensure product safety and compliance with UK regulations.
Context and Implications
This raid follows a previous MHRA operation in Northamptonshire targeting similar illicit weight-loss products. Notably, the Moulton Grange case was the first to uncover an operation producing its own branded weight-loss jab rather than counterfeit versions of existing medicines. The investigation highlights the ongoing challenges authorities face in combating illegal medicine manufacturing and distribution networks.
Understanding Research-Use Products
Some substances like retatrutide remain in clinical trial phases and are not approved for general use. Research-use products are intended solely for scientific investigation and not for human consumption outside controlled studies. It is important for consumers and researchers to distinguish between licensed medicines and experimental compounds to ensure safety and regulatory compliance.
For those interested in learning more about peptides, skincare, and wellbeing products, BuyOnlineMedication.com offers a comprehensive resource. Their shop provides a range of legitimate products, while the community supports informed discussions on product literacy and safe usage.
Research-use disclaimer: This article discusses products and substances that may be under scientific investigation or unlicensed. It does not provide medical advice or endorse the use of unapproved medicines.